Wegovy (Semaglutide)

Overview

Wegovy is a prescription injectable medication manufactured by Novo Nordisk that was approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or high cholesterol. It contains the same active ingredient as Ozempic—semaglutide—but is specifically formulated and dosed for weight loss rather than diabetes management.

What sets Wegovy apart from its diabetes-focused counterpart is the dosing. Wegovy's maintenance dose of 2.4 mg is significantly higher than Ozempic's maximum dose of 2 mg, which contributes to its more pronounced weight loss effects. The STEP clinical trial program demonstrated that patients on Wegovy lost an average of approximately 15% of their body weight, a result that was considered a breakthrough in obesity pharmacotherapy when the data was first published.

In March 2024, the FDA expanded Wegovy's indication to include the reduction of cardiovascular risk in adults with established cardiovascular disease who are either obese or overweight, making it the first weight loss medication to also carry a cardiovascular benefit indication. This was based on the landmark SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events.

How It Works

Wegovy works through the same mechanism as other semaglutide-based medications by mimicking the GLP-1 hormone that is naturally produced in the gut after eating. This hormone plays a critical role in appetite regulation, and Wegovy's synthetic version has been modified to remain active in the body for approximately one week, enabling the convenient once-weekly dosing schedule.

The weight loss mechanism is multi-faceted. Semaglutide acts on receptors in the hypothalamus—the brain's appetite control center—to reduce hunger and increase feelings of satiety. Patients frequently report a dramatic reduction in food cravings and what many describe as “food noise,” the persistent mental preoccupation with food that makes traditional dieting so difficult. This neurological effect is considered one of the most important aspects of the medication's weight loss mechanism.

In addition to its central nervous system effects, Wegovy slows the rate at which the stomach empties, leading to prolonged feelings of fullness after meals. It also improves insulin sensitivity and helps regulate blood sugar levels, which can reduce the cycle of blood sugar spikes and crashes that often drives overeating. Together, these mechanisms create a comprehensive approach to appetite and weight management that goes far beyond simple calorie restriction.

Dosing Schedule

Wegovy uses a carefully structured 16-week dose-escalation schedule designed to allow the body to gradually adjust and minimize gastrointestinal side effects. The schedule begins at 0.25 mg weekly for weeks 1–4, increases to 0.5 mg for weeks 5–8, then to 1 mg for weeks 9–12, followed by 1.7 mg for weeks 13–16, before reaching the maintenance dose of 2.4 mg from week 17 onward.

Each dose level comes in its own color-coded pre-filled pen, making it easy to identify the correct dose. The injection is administered subcutaneously in the abdomen, thigh, or upper arm. Patients should rotate injection sites to minimize the risk of lipodystrophy or injection site reactions. The medication should be stored in the refrigerator until first use, after which it can be kept at room temperature for up to 28 days.

Some patients may experience difficulty tolerating the higher doses. In these cases, healthcare providers may slow the escalation schedule, keeping patients on an intermediate dose for longer before advancing. If the 2.4 mg maintenance dose proves too difficult to tolerate, some physicians may maintain patients at the 1.7 mg level. It is important not to adjust dosing on your own—always work with your prescribing provider to find the right approach.

Weight Loss Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program provided the foundation for Wegovy's FDA approval and remains the most comprehensive dataset on semaglutide for weight management. In the pivotal STEP 1 trial, participants without diabetes who received Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Approximately one-third of participants lost 20% or more of their body weight.

In the STEP 2 trial, which focused on patients with Type 2 diabetes, average weight loss was approximately 9.6% of body weight—somewhat lower than in non-diabetic patients but still clinically significant. The STEP 3 trial combined Wegovy with intensive behavioral therapy and showed average weight loss of 16%, suggesting that combining medication with professional support yields the best outcomes. The STEP 5 trial extended the treatment period to two years and demonstrated sustained weight loss of approximately 15.2%.

It is important to set realistic expectations. While averages are useful, individual results vary considerably. Some patients lose significantly more than the average, while others may experience more modest results. Factors influencing outcomes include adherence to the dosing schedule, dietary changes, physical activity levels, starting weight, metabolic health, and genetic factors. Weight loss typically begins in the first few weeks and progresses most rapidly during the escalation period, with continued but slower loss after reaching the maintenance dose.

Side Effects

Gastrointestinal side effects are the most commonly reported adverse events with Wegovy. In clinical trials, approximately 44% of participants experienced nausea, 24% experienced diarrhea, 24% experienced vomiting, and 24% experienced constipation. These effects are most pronounced during the dose-escalation phase and typically decrease in frequency and intensity as the body adjusts to each new dose level.

More serious but less common side effects include pancreatitis, gallbladder disease (including gallstones), kidney injury, and allergic reactions. Like Ozempic, Wegovy carries a boxed warning about thyroid C-cell tumors based on rodent studies. Patients should be monitored for symptoms of thyroid tumors, pancreatitis, and gallbladder disease throughout treatment. There have also been reports of increased heart rate (typically 1–4 beats per minute on average) in clinical trials.

A side effect that deserves particular attention is the potential for muscle mass loss alongside fat loss. Rapid weight loss from any cause can lead to loss of lean body mass, and patients on Wegovy should be encouraged to maintain adequate protein intake and engage in resistance training to preserve muscle. Some patients also report hair thinning during rapid weight loss phases, which is typically temporary. Working with a healthcare team that includes nutritional support can help manage these concerns effectively.

Cost and Insurance

Wegovy has a list price of approximately $1,300–$1,400 per month, making it one of the more expensive medications on the market. The high cost reflects both the novelty of the treatment and the general reluctance of insurance companies to cover weight loss medications. Unlike Ozempic, which benefits from broader diabetes-related coverage, Wegovy often faces more restrictive coverage policies because it is classified as an anti-obesity medication.

Insurance coverage for Wegovy varies dramatically. Some commercial plans cover it with prior authorization, particularly when patients meet specific BMI and comorbidity criteria. Medicare historically has not covered anti-obesity medications, though legislative efforts have been underway to change this. Medicaid coverage varies by state. Novo Nordisk offers a savings program for commercially insured patients that may reduce costs, and patient assistance programs exist for qualifying uninsured individuals.

Supply shortages have been a significant issue for Wegovy since its launch. High demand combined with manufacturing constraints has led to periodic unavailability of certain dose strengths, particularly the lower escalation doses. These shortages can disrupt the carefully planned dose-escalation schedule and may delay treatment initiation for new patients. Novo Nordisk has been working to increase manufacturing capacity, and supply has gradually improved, but patients should be prepared for potential disruptions.

Who Is Wegovy For?

Wegovy is indicated for adults with a BMI of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or dyslipidemia. In December 2022, the FDA also approved Wegovy for adolescents aged 12 and older who meet obesity criteria, making it one of the few pharmacological options available for pediatric weight management.

The best candidates for Wegovy are individuals who have attempted lifestyle modifications (diet and exercise) without achieving sufficient weight loss, and who understand that the medication works best as part of a comprehensive approach that includes behavioral changes, nutritional guidance, and regular physical activity. Patients with established cardiovascular disease may also benefit from Wegovy's demonstrated cardiovascular risk reduction.

Wegovy is not appropriate for everyone. It should not be used during pregnancy, in patients with a personal or family history of medullary thyroid carcinoma or MEN2, or in combination with other GLP-1 receptor agonists. Patients considering Wegovy should have a thorough discussion with their healthcare provider about their medical history, weight loss goals, and the commitment required for long-term treatment—as weight regain is common after discontinuation, ongoing therapy may be necessary to maintain results.